Document:

Exhibit
10.1

CONSULTING AGREEMENT

This
agreement (the “Consulting Agreement”) is made effective as of March 1, 2006,
between Corgenix Medical Corporation, (“Corgenix” or the “Company”) and Gordon
E. Ens (“Mr. Ens”).

1.             Background.
Corgenix desires to engage Mr. Ens as an independent contractor to serve as a
consultant of the Company. This Consulting Agreement sets forth the terms and
conditions for such services.

2.             Services.  Mr. Ens will be engaged as an independent
contractor to provide certain consulting services to Corgenix on a part-time
basis related to a group of products related to aspirin resistance testing (the
“AspirinWorks Product Group”, as specified in Exhibit A, attached hereto), and
in that capacity, will report directly to the President of the Company (the “Corgenix
President”) or a person designated by the Corgenix President. The Corgenix
President shall establish reasonable duties, responsibilities, goals, timelines
and other requirements and expectations (collectively, the “Job Description”,
attached hereto as Exhibit B) of the consultant position to be performed by Mr.
Ens pursuant to this Consulting Agreement. Mr. Ens will devote sufficient time
in his performance of these duties to meet the requirements of the Job
Description. Mr. Ens’ duties will include work at Corgenix facilities in
Westminster, Colorado,  by conference
telephone call, or at other sites to be agreed to by both parties.

3.             Compensation.  During the term of this Agreement, Mr. Ens
will receive the following compensation for services.

(a)          A monthly fee, paid
monthly in arrears according to the following schedule

·                  March
2006 thru June 2006: $3,750 per month,

·                  July
2006 thru December 2006: $10,000 per month,

·                  January
2007 thru December 2007: $7,500 per month,

·                  January
2008 through the end of the Consulting Agreement: $7,500 per month.

(b)         Reimbursement for
reasonable business expenses actually incurred in the performance of consulting
services (including automobile, airfare, meals and lodging), such expenses to
be approved by the Corgenix President or his designee in advance.

(c)          Options to purchase
25,000 shares of Corgenix at an exercise price of 110% of the fair market value
per share on the date of  signing of this
agreement.

(d)         Other compensation as
determined by the Corgenix President.

4.             Independent
Contractor.  In the performance of
the consulting services, Mr. Ens shall be deemed to be an independent
contractor (and not an employee or agent of Corgenix) for all purposes under
any and all laws, whether existing or future, including without limitation
Social Security laws, unemployment insurance laws, and withholding and other
employment taxation laws.  Mr. Ens agrees
to comply with applicable laws, rules, and regulations in respect to
independent contractors, including without limitation, the payment of all taxes
required.

 

5.             Prior
Obligation or Restriction. Both parties warrant and agree that there is no
obligation or restriction and neither will assume any obligation or restriction
that would in any way interfere or be inconsistent with its duties and/or
responsibilities under this Consulting Agreement.

6.             Confidential
Information.  Mr. Ens shall not, at
any time during or following the work on behalf of Corgenix, directly or
indirectly distribute, use, or disclose to any person other than authorized
officers or personnel of Corgenix, trade secret or confidential information
relating to any activity of Corgenix (hereafter “Confidential Information”).  All notes, memoranda, or other writings made
by Mr. Ens or which may come into Mr. Ens’ possession while working with
Corgenix, or which relate in any way to or embody any Confidential Information
concerning any activity of Corgenix marketing and business ideas, shall be the
exclusive property of Corgenix and shall be kept on the Corgenix premises
except when required elsewhere in connection with its activities.  Upon completion of Mr. Ens’ services, Mr. Ens
will deliver to the Company all physical materials in his possession or within
his control relating to any Confidential Information which belongs to
Corgenix.  Mr. Ens shall execute all such
documents of assignment or other documents as Corgenix may deem reasonably
required to effect the provisions of this Paragraph 6.  The provisions of this Paragraph 6 shall
survive the termination of this Consulting Agreement.

7.             Term.  The initial term of this Consulting Agreement
shall commence on the date hereof and continue until December 31, 2007, after
which it will automatically expire unless,

(a)                                  Certain
revenue milestones have been met as specified on Exhibit C, attached hereto,
or,

(b)                                 Extended
by mutual consent of the Corgenix President and Mr. Ens.

8.             Miscellaneous.  This Consulting Agreement shall be governed
by the laws of the state of Colorado.  If
any term or provision of this Consulting Agreement is found by a court of
competent jurisdiction to be illegal or invalid for any reason whatsoever, such
illegality or invalidity shall not affect the validity of the remainder hereof.

IN
WITNESS WHEREOF, the parties hereto have executed this Consulting Agreement as
of the day and year first above written.

	
  

  	
   

  	
  Corgenix Medical Corporation

  	
   

  	
   

  	
  Gordon E. Ens

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
  

  	
   

  	
  By:

  	
  /s/ Gordon E. Ens

  	
   

  
	
   

  	
   

  	
  Douglass T. Simpson

  	
   

  	
   

  	
  Gordon E. Ens

  	
   

  
	
   

  	
   

  	
  President & CEO

  	
   

  	
   

  	
   

  	
   

  

 

 2
 

 

Exhibit A

AspirinWorks Product Group

updated March 1, 2006

1.               Metabolites of
Thromboxane ELISA kit

2.

 3
 

 

Exhibit B

Job Description

Actively
participate in all decisions, including technical development, marketing, sales
and education pertaining to AspirinWorks and related products.

Pursue and oversee
clinical studies with academic institutions, physicians,  reference laboratories and pharmaceutical
companies.

Network with
individuals and companies to identify additional AspirinWorks related opportunities.

Develop and
present educational seminars and workshops.

Assist in training
and supporting sales force.

Assist in training
and supporting technical support staff.

Assist in
preparation of sales and marketing materials including web site.

Provide assistance
in other areas by mutual consent between Corgenix President  and Mr. Ens.

 4
 

 

Exhibit C

Revenue Milestone for Term Extension

1.               If by 2007-12-31,
cumulative revenues from the AspirinWorks Product Line generated by Corgenix
exceed $ 2,420,224 the Consulting Agreement will be extended to 2009-01-01.

2.               If by 2008-07-01,
cumulative revenues from the AspirinWorks Product Line generated by Corgenix
exceed $ the Consulting Agreement will be extended to 2010-01-01.

 5Exhibit
10.2

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
LICENSE AGREEMENT, MARKED HERE BY ASTERISK, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

LICENSE AGREEMENT

THIS AGREEMENT is made as of March 1, 2007 (the “Effective Date”) by
and between Corgenix Medical Corporation, a Nevada corporation (“Licensee”), on
the one hand, and Creative Clinical Concepts, Inc., a Colorado corporation (“Licensor”),
on the other hand.

PREAMBLE

A.            Licensor is the sole
owner of the trademark “AspirinWorks” (and design) for conducting clinical
laboratory and home use tests to measure aspirin effectiveness, including U.S.
Trademark registration No. 2,688,842 for this trademark (the “Licensed Property”).

B.            Licensor
possesses both proprietary and public information related to the available and
potential market for measuring aspirin effectiveness and the use of thromboxane
and prostacyclin metabolites to determine the effect of aspirin on platelets or
endothelial cells, including, but not limited to names of contacts, customer
lists, market information, competitive information, and technology information
(“Market Information”).

C.            Licensee desires to
obtain, and the Licensor is willing to grant, a license for use of the Licensed
Property in association with products used in determining the effectiveness of
aspirin and/or anti-platelet therapy (including without limitation, diagnostic
products used to measure analytes in body fluids to aid in the determination of
the response of platelets to aspirin ingestion, and any additional products
measuring any thromboxane or prostacyclin metabolites for any clinical
condition) (the “Licensed Products”) on the terms and subject to the conditions
set forth in this Agreement.

D.            Licensor is willing
to provide the Market Information to the Licensee to aid Licensee in fulfilling
its responsibilities under this Agreement.

AGREEMENT

NOW, THEREFORE, in consideration of the above premises and of the
mutual covenants and conditions herein contained the Parties hereto have agreed
and do by these presents agree as follows:

1.             GRANT OF LICENSE.

(a)           Licensor hereby grants to the
Licensee, and the Licensee hereby accepts, a perpetual and exclusive license to
make, have made, use, and sell, Licensed Products using the Licensed Property
and to incorporate the Licensed Property into and market and sell 

 

such Licensed Property
with Licensed Products for distribution through retail outlets and other
distribution channels anywhere in the world (the “Licensed Territory”).  Licensor must not grant any other licenses
during the term of this Agreement for use of the Licensed Property.  For purposes of this Agreement, “Aspirin
Effectiveness Technology” means technology useful in the development,
manufacturing and/or marketing of any products used in determining the
effectiveness of aspirin and/or anti-platelet therapy.  In addition, Licensor hereby conveys the Market
Information to Licensee, which conveyance shall not be revocable.  The license granted pursuant to this Section
1 shall survive any termination of this Agreement by Licensee for breach by
Licensor.

(b)           Licensee shall have the right to use
the license granted by Licensor pursuant to this Agreement in connection with
any other asset or trademark, trade-name, patent or other intellectual property
owned or licensed by Licensee related to Aspirin Effectiveness Technology.
Licensor shall not use the Licensed Property. 
The Licensee shall have the right to enter into sublicensing agreements
with any other entity for the rights, privileges, and licenses granted
hereunder, so long as it obtains the prior written consent of the Licensor,
which consent shall not be unreasonably withheld, conditioned or delayed by
Licensor provided that any such sublicense agreement shall require that the
sublicensee will use its commercially best efforts to market and sell the
Licensed Products using the Licensed Property. Licensee shall provide Licensor
with at least forty-five days advance written notice of its intent to enter
into a sublicense agreement with any other entity or third party. Licensor
shall have forty-five days to advise Licensee as to whether Licensor intends to
withhold its consent to such sublicense; provided that such consent may not be
withheld if the Licensed Property is not altered in its presentation by
Licensee or sub-licensee and if the Licensed Property is being used in
connection with a Licensed Product.  In
the event Licensor withholds, conditions or delays its consent and the Licensee
believes such has been done unreasonably, the parties shall submit the dispute
to arbitration for resolution of the dispute. Licensee shall have the sole
discretion to use or not use the Licensed Property with respect to any
particular item of the Licensed Products. Licensee may directly or indirectly
export Licensed Products using the Licensed Property. Licensor and Licensee
agree the Licensed Property is Intellectual Property as defined in
Section 101 (35A) of the United States Bankruptcy Code. All
sublicensees shall be required to market, advertise, and list all Licensed
Products in their fee schedules and promotional materials using the Licensed
Property.

 (c)          Licensee
will use its commercially reasonable best efforts to market and sell the
Licensed Products using the Licensed Property. If, in the discretion of
Licensor, reasonably exercised based on objectively verified information and
data, Licensee has not provided its commercially reasonable best efforts,  then Licensor will have the right to notify
Licensee in writing of its desire to convene meetings to discuss a strategy to
enhance Net Sales of Licensed Products. 
Upon receipt of such notice, both parties must meet on no less than two
(2) occasions to discuss mutually acceptable solutions to the decline in Net
Sales of Licensed Products.  If however,
the parties are unable to resolve their concerns by meeting at least twice in a
thirty (30) day period following notice to Licensee, then Licensor may refer the
matter to arbitration pursuant to Section 10 below. Failure of  either party to effect or to perform the plan
set by the Arbitrator shall constitute a material breach of this Agreement.

 2
 

 

(d)           Licensee shall forgive all unpaid
past, present and future product development fees, costs and expenses, and all
unpaid  fees, costs and expenses related
thereto, due from Licensor to Licensee pursuant to that certain Product
Development, Manufacturing and Distribution Agreement dated May 13, 2004, and
Licensee shall forgive all unpaid fees, costs, expenses and charges including
all future fees, costs, expenses and charges related to the McMaster University
patent and license due from Licensor to McMaster University pursuant to that
certain License Agreement dated October 19, 2004. For accounting purposes, the
Licensee shall treat said forgiveness as an additional cost of the License.

(e)           Within ninety days from the date FDA
clearance is obtained for the Licensed Products and for a period of five years
thereafter, Licensee shall, at its sole expense, develop and maintain an
up-to-date and interactive internet website dedicated to the Licensed Products
to enable customers and potential customers to access information related to
obtaining, buying, understanding and using the Licensed Products. Licensor
shall cooperate as necessary to assist Licensee in the development and
maintenance of such website to assure that accurate information is available to
customers and potential customers as to the Licensed Products.

2.             TERM AND TERMINATION.

(a)           The term of this Agreement (“Term”)
shall commence as of the Effective Date and shall continue in perpetuity unless
properly terminated by either party as set forth in paragraph 2(c) following a
breach of this Agreement by the other party,.

(b)           Upon termination of this Agreement by
the Licensor, (i) Licensee shall have the right to sell the Licensed Products
that have been contracted for sale by the Licensee  prior to the date of termination for such
period of time (the “Sellout Period”) as is required to complete the sale of
such Licensed Products and shall pay Licensor royalties on the sales of such
Licensed Products during the Sellout Period in accordance with the provisions
of this Agreement; and (ii) except for Licensee’s right to dispose of Licensed
Products as set forth in clause (i) above, (1) Licensee shall release all of
Licensee’s rights in and to the Licensed Property and the license granted
pursuant to this Agreement; and (2) all rights of Licensee in and to the
Licensed Property shall revert to Licensor, except for any rights sublicensed
to a third party, which rights will not be revocable or infringed as a result
of the termination of this Agreement, and Licensee must make appropriate
arrangements with any sublicensee at that time. Upon termination of this
Agreement by the Licensee, all fees and royalties will be terminated effective
immediately.

(c)           Either party may terminate this
Agreement if a material breach of this Agreement by the other party is not
cured within thirty (30) days following written notice to the other party
specifying the default; provided that no termination may occur unless and until
the underlying dispute has been arbitrated and either party has violated in any
material respect the plan or order of the arbitrator.  Notwithstanding the foregoing, if, following
arbitration, the breaching party is diligently pursuing cure of the default,
but is not able to cure the default within the thirty (30) day period, the cure
period shall be extended for an additional thirty (30) days.

(d)           This Agreement shall terminate if the
Licensee becomes insolvent or files for protection or relief under any
provision of the United States Bankruptcy Code. In 

 3
 

 

such event, the parties agree that the Licensor shall
be entitled to relief from stay in any such bankruptcy proceeding, without
contest by Licensee, in order to allow Licensor to terminate this agreement. In
such event all rights of Licensee in and to the Licensed Property shall revert
to the Licensor.

3.             LICENSE FEES.  As consideration for the license granted
herein, and for such time as the Licensor is not in breach of, or deemed to be
in breach of, its obligations hereunder, the Licensee agrees to pay the
Licensor license fees in a combination of cash, shares of common stock of the
Licensee (“Corgenix Shares”), and warrants to purchase Corgenix Shares (“Corgenix
Warrants”) as described in this Section 3. 
The payments outlined in this Section 3 are subject in all events to the
limitations in Section 3(e).

(a)           On the Effective
Date, Licensee will pay Licensor:

(i)            $50,000 in cash;

(ii)           a number of Corgenix Shares equal to
$75,000 divided by the greater of (a) the average closing price of the Corgenix
Shares on the OTC:BB during the five trading days immediately preceding the
Effective Date and (b) [***] (the “Calculated Price”); and

(iii)          75,000 Corgenix Warrants with an
exercise price equal to the Calculated Price.

(b)           On the first
anniversary of Corgenix receiving FDA clearance of the first Licensed Product
(the “First Anniversary”), Licensee will pay to Licensor:

(i)            A cash payment equal to $50,000
multiplied by the First Anniversary Ratio, where:

a.              First Anniversary Ratio means
Total Cumulative Revenue divided by [***]; and

b.             Total Cumulative Revenue means
Licensee’s net sales revenue from all Licensed Products calculated from the
Effective Date through the First Anniversary.

(ii)           a number of
Corgenix Shares equal to the product of:

a.             $75,000 divided by the greater of
(i) the average closing price of the Corgenix Shares on the OTC:BB during the
five trading days immediately preceding the First Anniversary and (ii) [***]
(the “First Anniversary Calculated Price”)

 4
 

 

Multiplied by

b.             the First Anniversary Ratio.

(iii)          75,000 Corgenix Warrants with an
exercise price equal to First Anniversary Calculated Price.

(c)           On the second
anniversary of Corgenix receiving FDA clearance of the first Licensed Product
(the “Second Anniversary”), Licensee will pay to Licensor:

(i)            A cash payment equal to $50,000
multiplied by the Second Anniversary Ratio, where:

a.              Second Anniversary Ratio means
Total Cumulative Revenue divided by [***]; and

b.             Total Cumulative Revenue means
Licensee’s net sales revenue from all Licensed Products calculated from the
Effective Date through the Second Anniversary.

(ii)           a number of
Corgenix Shares equal to the product of:

a.             $75,000 divided by the greater of
(i) the average closing price of the Corgenix Shares on the OTC:BB during the
five trading days immediately preceding the Second Anniversary and (ii) [***]
(the “Second Anniversary Calculated Price”)

Multiplied by

b.             the Second
Anniversary Ratio.

(iii)          75,000 Corgenix Warrants with an
exercise price equal to the  Second
Anniversary Calculated Price.

(d)           On the third
anniversary of Corgenix receiving FDA clearance of the first Licensed Product
(the “Third Anniversary”), Licensee will pay to Licensor:

(i)            A cash payment equal to $50,000
multiplied by the Third Anniversary Ratio, where:

a.            
Third Anniversary Ratio means Total Cumulative Revenue divided by [***]; and

b.             Total
Cumulative Revenue means Licensee’s net sales revenue from all Licensed
Products calculated from the Effective Date through the Third Anniversary.

 5
 

 

(ii)           a number of Corgenix Shares equal to
the product of:

a.             $75,000
divided by the greater of (i) the average closing price of the Corgenix Shares
on the OTC:BB during the five trading days immediately preceding the Third
Anniversary and (ii) [***] (the “Third Anniversary Calculated Price”).

Multiplied by

b.             the Third Anniversary Ratio.

(iii)                               75,000
Corgenix Warrants with an exercise price equal to the  Third Anniversary Calculated Price.

(e)           Notwithstanding the
provisions of Sections 3(a)-(d) above:

(i)            the total amount of cash paid to
Licensor pursuant to this Section 3 will not exceed $200,000;

(ii)           the total number of Corgenix Shares
issued to Licensor pursuant to this Section 3 will not exceed $300,000 in
aggregate market value (with Corgenix Shares valued as of the dates such
Corgenix Shares are issued);

(iii)          the total number of Corgenix Warrants
issued to Licensor pursuant to this Section 3 will not exceed 300,000; and

(iv)          no cash, Corgenix Shares, or Corgenix
Warrants will be paid or issued after the Third Anniversary except as provided
in Section 4.

4.             ROYALTIES AND REPORTS.

(a)           As additional
consideration for the perpetual license herein granted, the Licensee agrees to
pay the Licensor earned royalties of: seven percent (7%) of aggregate “Net
Sales of Licensed Products” received by the Licensee or any affiliate of
Licensee from third parties for a period beginning on the Effective Date and
terminating ten (10) years later.  All
such royalties shall be paid by Licensee to Licensor within fifteen days after
the end of each calendar quarter based on the proceeds of Net Sales of Licensed
Products collected by Licensee during the immediately preceding calendar
quarter.  For purposes of this Agreement,
“Net Sales of Licensed Products” shall mean the total amounts received by
Licensee (or any affiliate of Licensee) from third party purchasers on all
sales by Licensee (or any affiliate of Licensee) of Licensed Products, after
deducting, to the extent not already deducted, normal and customary trade,
dealer, quantity, and cash discounts actually allowed; freight charges;
customary trade discounts actually taken; allowances for credits granted on
account of Licensed Products rejections, 

 6
 

 

returns, or price reductions; governmental sales,
consumption and other taxes and  charges
imposed on sales of Licensed Products; non payment of invoices in accordance
with their terms; and freight, insurance, customs, duties, and other landing
charges.  If payments to Licensee or any
affiliate of Licensee are made in currency other than United States Dollars,
then such currency shall be converted into its equivalent in United States
Dollars at the rates used by Licensee in its internal accounting procedures.

(b)           Within thirty (30)
days after the end of any quarter during the Term of this Agreement and the
Sellout Period, together with the payment of any royalty required to be paid
pursuant to this Agreement by Licensee to Licensor, the Licensee shall report
to the Licensor all royalties accruing under this Agreement during such
quarter.  Such reports shall indicate for
such quarter the aggregate payments on Net Sales of Licensed Products received
by the Licensee by item, and shall indicate the amount of the royalty due and
the manner in which such amount is determined. 
In case no royalty is due for any such quarter, the Licensee shall so
report and shall provide an accounting as to how Licensee determined no royalty
is due.

(c)           The Licensee shall
keep accurate records in sufficient detail to enable royalties due hereunder to
be determined, in accordance with generally accepted accounting principles,
consistently applied.  Upon the Licensor’s
request, and only after signing an appropriate confidentiality agreement, the
Licensee shall permit an independent auditor selected by the Licensor and at
Licensor’s sole expense to have access annually, upon the Licensor’s request,
during the Term hereof, during regular business hours and upon reasonable
notice (which shall be at least 5 business days) to the Licensee as may be
reasonably necessary to: (1) verify the accuracy of reports made under this
Agreement since the prior audit, and (2) determine insolvency of the Licensee
under section 2(d).  All information
obtained by Licensor in any such audit shall be kept strictly confidential by
Licensor and Licensor’s auditors and may not be used by Licensor or any other
person or entity for any reason whatsoever other than calculating amounts
payable to Licensor pursuant to this Agreement and shall not be divulged by
Licensor or its auditors to any person or entity other than to Licensor’s
attorneys, accountants, and as required by applicable law.  Licensee shall maintain all accounting
information relating to any royalty payment to Licensor pursuant to this
Agreement for three (3) years following the date of any such royalty
payment.  The provisions of this
Section shall survive termination of this Agreement.

5.             MANUFACTURE.

(a)           Licensee shall be
responsible for the manufacture, distribution and administration of the sale of
the Licensed Products at all times, including all costs relating thereto.

(b)           Licensor shall
assist and cooperate with Licensee, as reasonably requested by Licensee, in
connection with the manufacture of Licensed Products.  Licensor shall share with Licensee all
information in Licensor’s possession regarding manufacturers, including,
without limitation, factory names, contact information and current cost
information.

 7

 

(c)           Subject to that
certain Consulting Agreement between Licensee and Gordon Ens of even date
herewith and any other consulting or other agreement which may affect the
Licensor’s business or day to day operations thereof, Licensor and its agents,
attorneys, officers, directors, members, partners, shareholders, employees,
consultants and representatives shall not interfere with Licensee’s business in
any manner whatsoever, including, but not limited to, Licensee’s day to day
operations, administrative procedures, sales procedures, accounting methods,
personnel and customers, and shall not contact any of Licensee’s vendors,
suppliers, licensors, licensees or customers relating to the subject matter of
this Agreement and/or the Licensed Products without Licensee’s prior written
consent or discuss this Agreement with any person or entity (other than its own
employees and agents) without Licensee’s prior written consent.

(d)           Licensee shall
comply with standards of quality control reasonably established by Licensor in
connection with offering of the Licensed Products in order to protect and
maintain the goodwill of Licensor associated with the trademark. Licensee shall
use only a form and style of the trademark as approved by Licensor. Licensor
shall have the right to inspect and supervise the Licensee’s manufacture of
Licensed Products bearing the trademark, for the purpose of protecting and
maintaining the goodwill of Licensor associated with the trademark.

6.             LICENSOR’S NEW PRODUCT DEVELOPMENT.

(a)           In the event Licensor,
either directly or through any affiliate of Licensor, develops any new products
for measuring aspirin effectiveness and the use of thromboxane and prostacyclin
metabolites to determine the effect of aspirin on platelets or endothelial
cells, that Licensor (or affiliate) desires to distribute, Licensor shall give
written notice thereof to Licensee, which notice shall include all information
in Licensor’s possession or control relating to the development, manufacture
and sale of the new products.  Licensee
shall have ninety (90) days after receipt of Licensor’s notice within which to
advise Licensor in writing of Licensee’s interest in obtaining a license from
Licensor for the new products.  The
license shall be on substantially the same terms as this Agreement, except that
Licensor shall negotiate in good faith with Licensee with respect to the
royalty.  If  Licensor and Licensee are not able to reach
agreement on the royalty within ninety (90) days after Licensor’s receipt of
Licensee’s notice, Licensor shall have the right to enter into a license with
another party; provided that the royalty provisions shall not be more favorable
to the licensee than the provisions offered by Licensor to Licensee; and
further provided, that Licensor offers Licensee the right for a period of ten
(10) days after written notice from Licensor (which notice shall include a copy
of the proposed license) to enter into a license agreement with Licensor for
the new products on the terms of the proposed license with the other party
(i.e. a right of first refusal).

(b)           The provisions of
paragraph 6(a) will not be applicable to new products distributed without the
use of the Licensed Property. However, prior to pursuing the distribution of
the new products in such manner, either on its own or with another party,
Licensor shall discuss the distribution arrangements with Licensee for the
purpose 

 8
 

 

of determining if there is a mutually agreeable
arrangement between Licensor and Licensee for distribution of the products.

7.             REPRESENTATIONS,
WARRANTIES AND COVENANTS.

(a)           Licensor represents,
warrants and covenants to Licensee as follows: (i) Licensor owns all
rights in and to the Licensed Property free and clear of all liens and
encumbrances; (ii) Licensor has the full right, authority and power to
enter into this Agreement and to perform all its obligations hereunder;
(iii) Licensor’s execution, delivery and performance of this Agreement
will not violate the provisions of any agreement to which Licensor is a party;
and (iv) the Licensed Property does not infringe upon the intellectual
property rights of any other party. 
Neither Licensor nor Licensee makes any representation or warranty as to
the amount of receipts Licensee will derive from, or as to the quality or
success of, the Licensed Products.

(b)           Licensee represents
and warrants to Licensor as follows: (i) Licensee has full power and
authority to enter into this Agreement and perform its obligations herein; and
(ii) Licensee’s execution, delivery and performance of this Agreement will
not violate the provisions of any agreement to which Licensee is a party.

8.             INDEMNIFICATION. 
Licensor shall indemnify, hold harmless and defend Licensee, and its
parents, subsidiaries, affiliates, officers, directors and employees, against
any claims, liabilities, demands, causes of action, judgments, settlements and
expenses (including, but not limited to, reasonable attorneys’ fees and court
costs) arising out of or related to Licensee’s use of the Licensed Property as
authorized hereunder, including as a result of the infringement or alleged
infringement of any of the Licensed Property on the intellectual property
rights of any person or entity resulting from Licensee’s manufacture or sale of
Licensed Products using the Licensed Property.

9.             NOTICE.

(a)           All notice(s) of
every kind and description whatsoever under this Agreement shall be in writing
and shall be deemed to have been received when personally delivered or when
mailed through the U.S. Postal Service, postage prepaid, return receipt requested,
or when shipped by private express carrier, shipment charges prepaid, to the
party to whom delivery shall be made at the respective addresses as set out
below.

	
  To Licensor:

  	
   

  	
  Creative Clinical Concepts, Inc.

  
	
   

  	
   

  	
  224 East Cedar Ridge Court

  
	
   

  	
   

  	
  Andover, Kansas 67002

  
	
   

  	
   

  	
   

  
	
  To Licensee:

  	
   

  	
  Corgenix Medical Corporation

  
	
   

  	
   

  	
  11575 Main Street, Suite 400

  Broomfield, Colorado 80020

  

 

 9
 

 

 

	
  With a copy to:

  	
   

  	
  Robert P. Attai

  Otten, Johnson, Robinson, Neff &

  Ragonetti, P.C.

  950 17th Street

  Denver, CO 80202

  

 

10.           ARBITRATION.  Subject to Section 1(c), the parties agree to
submit to binding arbitration any and all claims, disputes and controversies
between or among them relating to this Agreement.  Arbitration must proceed in Denver, Colorado,
be governed by Colorado law, and be conducted in accordance with the Commercial
Arbitration Rules of the American Arbitration Association (“AAA”).  Judgment upon the award rendered by the arbitrators
may be entered in any court having jurisdiction.  Arbitration must be before a single, neutral
arbitrator with at least 10 years of experience in commercial business dealings
involving medical technology.  The AAA
shall submit a list of persons meeting the criteria outlined above and the
parties must select the arbitrator in the manner established by the AAA.  The arbitrator will not be authorized to
revoke the license granted pursuant to Section 1 of this agreement, but will be
authorized to revoke Licensee’s exclusivity with respect to such Licensed
Property.

11            MISCELLANEOUS.

(a)           This Agreement
constitutes the entire understanding between the parties hereto relating to the
subject matter of this Agreement. This agreement supplements, but does not
supersede the Product Development, Manufacturing and Distribution Agreement
between the parties, dated May 13, 2004.

(b)           No provision of this
Agreement may be amended or added to except by an agreement in writing signed
by all of the parties hereto.

(c)           This Agreement and
the rights, obligations and duties hereunder shall not be assigned by any party
without the prior written consent of the other party, except in connection with
the sale or other transfer by the party of all or substantially all of the party’s
business and assets in a transaction in which the transferee agrees in writing
to be bound by all of the terms of this Agreement. This Agreement shall be
binding on the parties, their successors, sublicensees, assigns, affiliates and
fiduciaries.

(d)           This Agreement shall
be governed by the laws of State of Colorado (without regard to its so-called
choice of law rules).

(e)           Any provision of
this Agreement which is unenforceable in any jurisdiction shall, as to such
jurisdiction, be ineffective only to the extent of such unenforceability
without invalidating the remaining provisions of this Agreement or affecting
the enforceability of such provision in any other jurisdiction.

(f)            The descriptive
headings of this Agreement are intended for reference only and shall not affect
the construction or interpretation of this Agreement.

 10
 

 

(g)           No forbearance,
delay or indulgence by either party in enforcing the provisions of this
Agreement shall prejudice or restrict the rights of that party, nor shall any
waiver of its rights operate as a waiver of any subsequent breach.

(h)           The parties will,
without further consideration, do any further acts and deliver all further
assurances, documents, as shall be necessary or required to fully perform and
carry out the terms of this Agreement.

(i)            The parties have
entered into this Agreement as independent contractors only, and nothing
contained in this Agreement places or shall be construed to place the parties
in the relationship of legal representation, employer-employee, partners, joint
venturers, or agency, and neither party will have the power or authority to
obligate or bind the other party in any manner. 
There is no intent to create third party beneficiary status in any other
person and no third party shall have any right to enforce any provision hereof.

(j)            In the event either
party commences any legal action to enforce the provisions of this Agreement
following a breach thereof by the other party, the prevailing party in such
action shall be entitled to recover from the other party, in addition to any
other legal or equitable relief granted, all reasonable attorneys’ fees and
costs in such action.

(k)           This Agreement may
be executed in one or more counterparts, all of which, together, shall be
deemed one and the same original document.

(l)            This Agreement shall be effective on
the date of execution of this Agreement by the parties, which date shall be the
Effective Date as referred to in the provisions set forth in this Agreement.

 11
 

 

IN WITNESS WHEREOF, the parties have executed this
Agreement as of the Effective Date.

	
  

  	
   

  	
  LICENSEE

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Corgenix Medical Corporation

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By: 

  	
   

  	
  /s/ Douglass T. Simpson

  
	
   

  	
   

  	
   

  	
   

  	
  Douglass T.
  Simpson

  
	
   

  	
   

  	
   

  	
   

  	
  President and
  CEO

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  LICENSOR

  
	
   

  	
   

  	
  Creative
  Clinical Concepts, Inc.

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By: 

  	
   

  	
  /s/ Gordon E. Ens

  
	
   

  	
   

  	
   

  	
   

  	
  Gordon E. Ens

  
	
   

  	
   

  	
   

  	
   

  	
  President

  

 

 12
 

 

EXHIBIT A

LICENSED
PROPERTY

1.               Trademarks
depicted on Exhibit A-1

2.               All
rights under the License Agreement with McMaster University dated October 19,
2004, attached hereto as Exhibit A-2

 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]